Progression of Tricuspid Regurgitation After Surgery for Ischemic Mitral Regurgitation |
| |
Authors: | Philippe B. Bertrand Jessica R. Overbey Xin Zeng Robert A. Levine Gorav Ailawadi Michael A. Acker Peter K. Smith Vinod H. Thourani Emilia Bagiella Marissa A. Miller Lopa Gupta Michael J. Mack A. Marc Gillinov Gennaro Giustino Alan J. Moskowitz Annetine C. Gelijns Michael E. Bowdish Patrick T. O’Gara Yanne Toulgoat-Dubois |
| |
Affiliation: | 1. Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA;2. Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York, USA;3. Section of Adult Cardiac Surgery, University of Virginia, Charlottesville, Virginia, USA;4. Division of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA;5. Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA;6. Cardiothoracic Surgery, Piedmont Heart Institute, Atlanta, Georgia, USA;7. Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA;8. Cardiothoracic Surgery, Baylor Research Institute, Baylor Scott & White Health, Plano, Texas, USA;9. Department of Thoracic & Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio, USA;10. Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California, USA;11. Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts, USA;12. Division of Cardiac Surgery, University of Maryland School of Medicine, Baltimore, Maryland, USA |
| |
Abstract: | BackgroundWhether to repair nonsevere tricuspid regurgitation (TR) during surgery for ischemic mitral valve regurgitation (IMR) remains uncertain.ObjectivesThe goal of this study was to investigate the incidence, predictors, and clinical significance of TR progression and presence of ≥moderate TR after IMR surgery.MethodsPatients (n = 492) with untreated nonsevere TR within 2 prospectively randomized IMR trials were included. Key outcomes were TR progression (either progression by ≥2 grades, surgery for TR, or severe TR at 2 years) and presence of ≥moderate TR at 2 years.ResultsPatients’ mean age was 66 ± 10 years (67% male), and TR distribution was 60% ≤trace, 31% mild, and 9% moderate. Among 2-year survivors, TR progression occurred in 20 (6%) of 325 patients. Baseline tricuspid annular diameter (TAD) was not predictive of TR progression. At 2 years, 37 (11%) of 323 patients had ≥moderate TR. Baseline TR grade, indexed TAD, and surgical ablation for atrial fibrillation were independent predictors of ≥moderate TR. However, TAD alone had poor discrimination (area under the curve, ≤0.65). Presence of ≥moderate TR at 2 years was higher in patients with MR recurrence (20% vs. 9%; p = 0.02) and a permanent pacemaker/defibrillator (19% vs. 9%; p = 0.01). Clinical event rates (composite of ≥1 New York Heart Association functional class increase, heart failure hospitalization, mitral valve surgery, and stroke) were higher in patients with TR progression (55% vs. 23%; p = 0.003) and ≥moderate TR at 2 years (38% vs. 22%; p = 0.04).ConclusionsAfter IMR surgery, progression of unrepaired nonsevere TR is uncommon. Baseline TAD is not predictive of TR progression and is poorly discriminative of ≥moderate TR at 2 years. TR progression and presence of ≥moderate TR are associated with clinical events. (Comparing the Effectiveness of a Mitral Valve Repair Procedure in Combination With Coronary Artery Bypass Grafting [CABG] Versus CABG Alone in People With Moderate Ischemic Mitral Regurgitation, NCT00806988; Comparing the Effectiveness of Repairing Versus Replacing the Heart’s Mitral Valve in People With Severe Chronic Ischemic Mitral Regurgitation, NCT00807040) |
| |
Keywords: | ischemic heart disease mitral valve regurgitation mitral valve surgery tricuspid annular dilation tricuspid valve regurgitation CABG" },{" #name" :" keyword" ," $" :{" id" :" kwrd0040" }," $$" :[{" #name" :" text" ," _" :" coronary artery bypass grafting ICD" },{" #name" :" keyword" ," $" :{" id" :" kwrd0050" }," $$" :[{" #name" :" text" ," _" :" implantable cardioverter-defibrillator IMR" },{" #name" :" keyword" ," $" :{" id" :" kwrd0060" }," $$" :[{" #name" :" text" ," _" :" ischemic mitral valve regurgitation MACE" },{" #name" :" keyword" ," $" :{" id" :" kwrd0070" }," $$" :[{" #name" :" text" ," _" :" major adverse clinical events MR" },{" #name" :" keyword" ," $" :{" id" :" kwrd0080" }," $$" :[{" #name" :" text" ," _" :" mitral regurgitation MV" },{" #name" :" keyword" ," $" :{" id" :" kwrd0090" }," $$" :[{" #name" :" text" ," _" :" mitral valve ROC" },{" #name" :" keyword" ," $" :{" id" :" kwrd0100" }," $$" :[{" #name" :" text" ," _" :" receiver-operating characteristic RV" },{" #name" :" keyword" ," $" :{" id" :" kwrd0110" }," $$" :[{" #name" :" text" ," _" :" right ventricular TR" },{" #name" :" keyword" ," $" :{" id" :" kwrd0120" }," $$" :[{" #name" :" text" ," _" :" tricuspid regurgitation |
本文献已被 ScienceDirect 等数据库收录! |
|